Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results ...

Eurolab has achieved a landmark legal victory in South Africa, allowing the company to produce and sell a generic version of ...

The matter arose after Eurolab identified the potential of enzalutamide, an inhibitor, used in the treatment of prostate ...

IN the face of a legal challenge by a multi-national pharmaceutical giant, a South African pharmaceutical company has fought ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

"We appreciate the Chinese government's strong commitment to deepening reforms and expanding high-standard opening-up, with a ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...